Form 4: Krystal Biotech CEO Krish S. Krishnan Reports Stock Transactions

CEO Krish S. Krishnan reports multiple transactions involving Krystal Biotech stock, including acquisitions from performance stock unit and restricted stock unit vesting, and disposals for tax withholding.

Summary

• On February 26, 2025, Krish S. Krishnan, the CEO of Krystal Biotech, surrendered 4,721 shares of common stock at $176.39 for tax withholding related to the vesting of 10,200 restricted stock awards.
• On February 28, 2025, Krishnan acquired shares through the vesting of 12,500 performance stock units (PSUs), 8,750 restricted stock units (RSUs), and 26,250 PSUs.
• Also on February 28, 2025, Krishnan disposed of 5,786, 4,050 and 12,149 shares at $179.25 for tax withholding related to the vesting of PSUs and RSUs.
• Krishnan's spouse, Suma M. Krishnan, also acquired and disposed of shares on February 28, 2025, due to the vesting of PSUs, and surrendered shares for tax withholding.
• Krishnan also reported that he indirectly owns 90,000 shares through the Krishnan Spousal Trust and 50,000 shares through the Krishnan Family Trust.
• Krishnan was granted 39,300 stock options (right to buy) at $179.25, exercisable beginning February 28, 2026, and expiring February 28, 2035.
• Krishnan was also granted 22,900 restricted stock units (RSUs) that vest in four equal annual installments beginning on February 28, 2026.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions by an insider. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Positives

• The vesting of PSUs indicates that performance criteria set by the company's Compensation Committee were met.
• The granting of stock options and RSUs to the CEO aligns his interests with those of the shareholders.

Future Outlook

The document outlines future vesting dates for stock options and restricted stock units, indicating continued equity-based compensation for the reporting person.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors to gauge management's sentiment and confidence in the company's prospects.

Comparison to Industry Standards

• Equity compensation is a common practice among publicly traded companies, particularly in the biotech industry, to incentivize executives and align their interests with shareholders.
• Vesting schedules for stock options and RSUs typically range from three to five years, with annual or quarterly vesting installments.
• Tax withholding practices related to equity compensation are standard procedure to ensure compliance with tax regulations.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in the number of outstanding shares.
• The vesting of equity awards incentivizes the CEO and his spouse, who also works at the company, to continue their service and contribute to the company's success.

Key Dates